0.37
0.025 (7.25%)
0.025 (7.25%)
Upgrade to Real-Time
Market Closed
Best deals to access real time data! |
|
Small Cap Basic
Monthly Subscription
for only
|
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Mateon Therapeutics Inc (QB) | MATN | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.025 | 7.25% | 0.37 | 16:51:35 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.358 | 0.358 | 0.37 | 0.37 | 0.345 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 0.36 | 0.40 | 0.04 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 143 | 725,896 | $ 0.364249 | $ 264,407 | - | 0.076 - 0.38 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:59:44 | 9,000 | $ 0.37 | USD |
Mateon Therapeutics (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 33.15M | 89.58M | 26.84M | $ - | $ - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 491.00 | $ - | 0.00% | - | - |
Mateon Therapeutics (QB) News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MATN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.29 | 0.38 | 0.26 | 0.3286994 | 541,934 | 0.08 | 27.59% |
| 1 Month | 0.21 | 0.38 | 0.2011 | 0.2728457 | 337,472 | 0.16 | 76.19% |
| 3 Months | 0.172 | 0.38 | 0.17 | 0.2459731 | 203,979 | 0.198 | 115.12% |
| 6 Months | 0.23 | 0.38 | 0.16 | 0.2358842 | 166,463 | 0.14 | 60.87% |
| 1 Year | 0.16 | 0.38 | 0.076 | 0.2068445 | 201,407 | 0.21 | 131.25% |
| 3 Years | 0.185 | 0.38 | 0.05 | 0.1976191 | 98,778 | 0.185 | 100.0% |
| 5 Years | 0.34 | 0.889 | 0.05 | 0.2443886 | 95,641 | 0.03 | 8.82% |
Mateon Therapeutics (QB) Description
| Mateon has three major business segments: 1) PointR- developer of vision grid/cluster computing/AI to support drug development. 2) Mateon/Oxigene- developer of Vascular Disrupting Agent (CA4P and Oxi4503). FDA granted CA4P rare pediatric designation for pediatric melanoma in 2020 and OXi4503 rare pediatric designation for pediatric ALL. 3) Oncotelic- developer of OT-101 - an antisense against TGF-beta- for the treatment of cancers. OT-101 completed phase 2 with good safety and efficacy against pancreatic cancer, glioblastoma, and melanoma. OT-101 also been granted rare pediatric designation against pediatric DIPG in 2019. OT-101 is also being deployed against COVID-19. OT-101 is in phase 2 clinical trial against COVID. We are also developing Artemisinin in phase 4 clinical trial against COVID. It is approved by India for symptoms frequently observed in COVID. It is being launch by end of 2020. Global launch will be soon after. |
